Clinical Lung Cancer

metrics 2024

Transforming knowledge into practice in lung cancer treatment.

Introduction

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.

Metrics 2024

SCIMAGO Journal Rank1.26
Journal Impact Factor3.30
Journal Impact Factor (5 years)3.40
H-Index74
Journal IF Without Self3.30
Eigen Factor0.01
Normal Eigen Factor1.71
Influence1.16
Immediacy Index1.00
Cited Half Life4.80
Citing Half Life5.50
JCI0.80
Total Documents2367
WOS Total Citations4386
SCIMAGO Total Citations18889
SCIMAGO SELF Citations647
Scopus Journal Rank1.26
Cites / Document (2 Years)3.23
Cites / Document (3 Years)3.31
Cites / Document (4 Years)3.41

Metrics History

Rank 2024

Scopus

Pulmonary and Respiratory Medicine in Medicine
Rank #31/155
Percentile 80.00
Quartile Q1
Oncology in Medicine
Rank #98/404
Percentile 75.74
Quartile Q1
Cancer Research in Biochemistry, Genetics and Molecular Biology
Rank #85/230
Percentile 63.04
Quartile Q2

IF (Web Of Science)

ONCOLOGY
Rank 118/322
Percentile 63.50
Quartile Q2

JCI (Web Of Science)

ONCOLOGY
Rank 116/322
Percentile 63.98
Quartile Q2

Quartile History

Similar Journals

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Exploring innovations in cancer treatment and blood health.
Publisher: ELSEVIER SCIENCE INCISSN: 1040-8428Frequency: 12 issues/year

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.

Thoracic Cancer

Transforming insights into impactful treatments.
Publisher: WILEYISSN: 1759-7706Frequency: 24 issues/year

Thoracic Cancer is a distinguished open-access journal published by WILEY, dedicated to advancing the field of thoracic oncology. Since its establishment in 2010, the journal has emerged as a crucial platform for the dissemination of innovative research and clinical studies relating to lung cancer and other thoracic malignancies. With a commendable impact reflected in its 2023 Q2 rankings in the categories of Medicine (Miscellaneous), Oncology, and Pulmonary and Respiratory Medicine, the journal features high-quality articles that are vital for researchers, clinicians, and students aspiring to enhance their understanding of thoracic cancers. Operating out of Australia, Thoracic Cancer has embraced a commitment to open access since 2015, ensuring that vital research is readily available to a global audience. The journal's rigorous peer-review process and emphasis on novel findings make it an indispensable resource for professionals seeking to stay at the forefront of this rapidly evolving field.

Current Problems in Cancer: Case Reports

Transforming patient care through diverse oncology perspectives.
Publisher: ELSEVIERISSN: 2666-6219Frequency: 2 issues/year

Current Problems in Cancer: Case Reports is a prominent scholarly journal published by Elsevier, focusing on critical case reports within the field of oncology. Since its transition to Open Access in 2020, it has enhanced accessibility for researchers and healthcare professionals seeking to share and discuss unique clinical scenarios and insights that advance cancer treatment and patient care. Operating from the United States, this journal aims to address the important and often intricate challenges faced in oncology, facilitating a platform for knowledge exchange and the exploration of new perspectives in cancer management. Despite its current Q4 category ranking in the 2023 oncology category of Scopus with a rank of #359/404, its goal is to enrich the academic discourse by featuring diverse case reports and promoting evidence-based practices. As the journal evolves from 2021 to 2024, it seeks to impact the field by inviting researchers, professionals, and students to contribute their findings, ultimately fostering a collaborative environment for tackling the complexities of cancer.

Cancer Medicine

Unveiling the future of cancer therapies and treatments.
Publisher: WILEYISSN: 2045-7634Frequency: 12 issues/year

Cancer Medicine is a leading open access journal published by WILEY, focusing on innovative research and advancements in the fields of Cancer Research, Oncology, and Radiology, with an impressive impact evidenced by its 2023 Q2 ranking in Cancer Research and Q1 rankings in both Oncology and Radiology, Nuclear Medicine and Imaging. With an ISSN of 2045-7634, this journal has been committed to disseminating pivotal findings since its inception in 2012, serving as a vital platform for researchers, practitioners, and students alike. The journal proudly embodies the spirit of open access, ensuring that groundbreaking cancer research is accessible to a global audience. Located in the United Kingdom, it spans a wide array of topics, promising comprehensive insights into cancer therapies, molecular mechanisms, and imaging techniques, thereby significantly contributing to the enhancement of cancer care and treatment outcomes. Researchers interested in exploring the latest advancements in cancer medicine will find this journal an indispensable resource.

Lancet Respiratory Medicine

Advancing knowledge for a healthier future in respiratory care.
Publisher: ELSEVIER SCI LTDISSN: 2213-2600Frequency: 12 issues/year

The Lancet Respiratory Medicine, published by Elsevier in the United Kingdom, is a premier journal dedicated to the field of pulmonary and respiratory medicine. With its impressive impact factor and a prestigious ranking of #1 out of 155 in its category as of 2023, it holds a remarkable position in advancing research and clinical practices in respiratory health. The journal invites original research, reviews, and clinical studies that aim to propel the understanding of respiratory diseases, fostering innovations in treatment and management strategies. Operating under a Q1 category in Scopus rankings, it is an essential platform for researchers, healthcare professionals, and students who are committed to enhancing patient care and advancing knowledge in this crucial area of medicine. The Lancet Respiratory Medicine remains a vital resource for the latest findings and discussions shaping the future of respiratory health.

European Urology Oncology

Transforming clinical practices with groundbreaking findings.
Publisher: ELSEVIERISSN: Frequency: 6 issues/year

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.

JOURNAL OF CLINICAL ONCOLOGY

Fostering a community dedicated to advancing cancer knowledge.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0732-183XFrequency: 36 issues/year

Journal of Clinical Oncology is a premier academic journal published by Lippincott Williams & Wilkins, dedicated to the field of oncology and cancer research. Since its inception in 1983, this influential journal has consistently ranked in the Q1 category across multiple disciplines, including cancer research, medicine, and oncology, reflecting its critical role in shaping the future of cancer therapeutics and patient care. With a Scopus ranking of #9 in Medicine - Oncology and #6 in Biochemistry, Genetics and Molecular Biology - Cancer Research, Journal of Clinical Oncology publishes cutting-edge original research, reviews, and clinical updates that are essential for professionals, researchers, and students alike. Although it does not currently offer open access options, it provides invaluable insights and evidence-based findings that are crucial for advancing oncological knowledge and improving patient outcomes globally. The journal’s continued commitment to excellence ensures its place as a vital resource in the oncological community.

Oncology Research and Treatment

Elevating cancer research to new heights.
Publisher: KARGERISSN: 2296-5270Frequency: 10 issues/year

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

THORAX

Navigating the complexities of pulmonary medicine.
Publisher: BMJ PUBLISHING GROUPISSN: 0040-6376Frequency: 12 issues/year

THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.

Current Pulmonology Reports

Exploring the latest innovations in pulmonology.
Publisher: SPRINGERISSN: Frequency: 4 issues/year

Current Pulmonology Reports, published by SPRINGER, stands as a vital resource in the realm of respiratory health, delivering peer-reviewed research that informs clinical practices and advances understanding within the field of pulmonology. With an E-ISSN of 2199-2428, this journal captures the latest findings and technological innovations pertinent to respiratory diseases, treatment protocols, and patient management strategies. Although currently classified as non-open access, it ensures robust dissemination of significant research contributions which are essential for professionals and scholars alike. The journal's objective is not only to foster a deeper understanding of lung health issues but also to bridge the gap between research and application, thereby impacting real-world practices. As the demand for comprehensive studies in pulmonology continues to grow, Current Pulmonology Reports seeks to maintain its position as a premier outlet for quality research, ultimately bettering outcomes in respiratory medicine.